These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 11058037

  • 21. Preliminary in vivo and ex vivo evaluation of the 5-HT2A imaging probe [(18)F]MH.MZ.
    Herth MM, Piel M, Debus F, Schmitt U, Lüddens H, Rösch F.
    Nucl Med Biol; 2009 May; 36(4):447-54. PubMed ID: 19423013
    [Abstract] [Full Text] [Related]

  • 22. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats.
    Varty GB, Bakshi VP, Geyer MA.
    Neuropsychopharmacology; 1999 Apr; 20(4):311-21. PubMed ID: 10088132
    [Abstract] [Full Text] [Related]

  • 23. Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907.
    Wadenberg ML, Hicks PB, Richter JT, Young KA.
    Biol Psychiatry; 1998 Sep 15; 44(6):508-15. PubMed ID: 9777184
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis.
    Hemrick-Luecke SK, Evans DC.
    Neuropharmacology; 2002 Feb 15; 42(2):162-9. PubMed ID: 11804612
    [Abstract] [Full Text] [Related]

  • 25. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT2A receptor antagonist.
    Marek GJ, Aghajanian GK.
    Eur J Pharmacol; 1994 Jul 01; 259(2):137-41. PubMed ID: 7957607
    [Abstract] [Full Text] [Related]

  • 26. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
    Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C.
    J Pharmacol Exp Ther; 1996 May 01; 277(2):968-81. PubMed ID: 8627580
    [Abstract] [Full Text] [Related]

  • 27. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD, Ettrup A, Herth MM, Dyssegaard A, Ratner C, Gillings N, Knudsen GM.
    Synapse; 2013 Jun 01; 67(6):328-37. PubMed ID: 23390031
    [Abstract] [Full Text] [Related]

  • 28. Effects of serotonin 5-HT(2A/2C) antagonists on associative learning in the rabbit.
    Welsh SE, Romano AG, Harvey JA.
    Psychopharmacology (Berl); 1998 May 01; 137(2):157-63. PubMed ID: 9630002
    [Abstract] [Full Text] [Related]

  • 29. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone.
    Schreiber R, Brocco M, Millan MJ.
    Eur J Pharmacol; 1994 Oct 13; 264(1):99-102. PubMed ID: 7530204
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients.
    Talvik-Lotfi M, Nyberg S, Nordström AL, Ito H, Halldin C, Brunner F, Farde L.
    Psychopharmacology (Berl); 2000 Mar 13; 148(4):400-3. PubMed ID: 10928313
    [Abstract] [Full Text] [Related]

  • 32. Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.
    Simpson HB, Slifstein M, Bender J, Xu X, Hackett E, Maher MJ, Abi-Dargham A.
    Biol Psychiatry; 2011 Nov 01; 70(9):897-904. PubMed ID: 21855857
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML.
    J Neural Transm (Vienna); 1998 Nov 01; 105(4-5):365-96. PubMed ID: 9720968
    [Abstract] [Full Text] [Related]

  • 35. Agonist and antagonist binding to rabbit cortical 5-HT2A receptors: opposite effects of magnesium.
    Aloyo VJ, Salt GL, Hoffman ME, Harvey JA.
    Ann N Y Acad Sci; 1998 Dec 15; 861():280. PubMed ID: 9928290
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.
    Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM.
    Synapse; 2005 Dec 15; 58(4):249-57. PubMed ID: 16206185
    [Abstract] [Full Text] [Related]

  • 39. Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging.
    Fu X, Tan PZ, Kula NS, Baldessarini R, Tamagnan G, Innis RB, Baldwin RM.
    J Med Chem; 2002 May 23; 45(11):2319-24. PubMed ID: 12014970
    [Abstract] [Full Text] [Related]

  • 40. The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.
    Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E.
    Psychiatry Res; 2011 Dec 30; 194(3):230-234. PubMed ID: 22079057
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.